Vaxart Stock (NASDAQ:VXRT)


Chart

Previous Close

$0.61

52W Range

$0.52 - $1.54

50D Avg

$0.79

200D Avg

$0.87

Market Cap

$141.04M

Avg Vol (3M)

$1.53M

Beta

0.70

Div Yield

-

VXRT Company Profile


Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

109

IPO Date

Dec 11, 1981

Website

VXRT Performance


Latest Earnings Call Transcripts


Q2 22Aug 08, 22 | 9:11 PM
Q2 17Feb 03, 17 | 5:00 PM
Q1 17Nov 05, 16 | 5:00 PM

Peer Comparison


TickerCompany
CODXCo-Diagnostics, Inc.
NVAXNovavax, Inc.
INOInovio Pharmaceuticals, Inc.
OCGNOcugen, Inc.